Solar-StageNCT06235151
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 17 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Primary completion date changed from estimate of Sep 2026 to Oct 30, 2026
- Enrollment target: estimated 439 to confirmed 443
Notable Eligibility criteria expanded, about 12 words Show 5 more changesShow less
- Primary and study completion dates: Sep 2026 to Oct 2026
- Interventions: Copper Cu 64 PSMA I&T (Drug) to Copper Cu 64 PSMA I&T (Drug)
- Secondary endpoints: details revised at 3 of 3 entries
- Study description revised
- Site details revised at 3 of 43 sites
- Minor Enrollment closed, study ongoing
- Study sites: 44 to 43
- Minor Study sites: 43 to 44
- Secondary endpoints: 2 to 3
- Minor Primary and study completion pushed from Mar 2026 to Sep 2026
- Site details revised at 1 of 43 sites
Show 11 earlier versionsHide 11 earlier versions
- Minor Enrollment target: 323 to 439
- Study description revised
- Minor Study sites: 41 to 43v12
- Minor Study sites: 40 to 41v11
- Notable Primary and study completion dates: Jul 2025 to Mar 2026
- Study sites: 39 to 40
- Minor Study sites: 38 to 39v9
- Minor Study sites: 39 to 38v7
- Minor Study sites: 36 to 39v6
- Minor Study sites: 35 to 36v5
- Minor Study sites: 17 to 35v4
- Notable Eligibility criteria expanded, about 1 word
- Study sites: 9 to 17
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 9
- Start date changed from estimate of Feb 2024 to Apr 1, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Sensitivity
Timeframe: 4 Hours
Specificity
Timeframe: 4 Hours
Secondary (3)
Inter-reader and intra-reader agreement of copper Cu 64 PSMA I&T PET/CT interpretation on a per-patient basis
Incidence of adverse events in copper Cu 64 PSMA I&T injection
Positive Predictive Value and Negative Predictive Value
Arms and interventions
Diagnostic Imaging with Copper Cu 64 PSMA I&TExperimental
Copper Cu 64 PSMA I\&T Injection
Drugs: Copper Cu 64 PSMA I&T
Sites
43 sites in 1 country